2 results
Approved WMOCompleted
To assess safety, tolerability and pharmacokinetics of a single subcutaneous administration of HPV-NIRD1.
Approved WMOCompleted
Primary Objective: To assess the sensitivity and specificity of rhPSMA-7.3 (18F) PET in detecting N1 disease on a patient level compared to the histopathology of pelvic lymphatic tissue removed during RP and PLND. At least one positive pelvic LN on…